Department of Oncology, Taipei Veterans General Hospital, Taipei, Taiwan.
School of Medicine, College of Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan.
BMJ Open Diabetes Res Care. 2023 Mar;11(2). doi: 10.1136/bmjdrc-2022-003262.
Adapted Diabetes Complications Severity Index (aDCSI) is a commonly used severity measure based on the number and severity of diabetes complications using diagnosis codes. The validity of aDCSI in predicting cause-specific mortality has yet to be verified. Additionally, the performance of aDCSI in predicting patient outcomes compared with Charlson Comorbidity Index (CCI) remains unknown.
Patients aged 20 years or older with type 2 diabetes prior to January 1, 2008 were identified from the Taiwan National Health Insurance claims data and were followed up until December 15, 2018. Complications for aDCSI including cardiovascular, cerebrovascular and peripheral vascular disease, metabolic disease, nephropathy, retinopathy and neuropathy, along with comorbidities for CCI, were collected. HRs of death were estimated using Cox regression. Model performance was evaluated by concordance index and Akaike information criterion.
1,002,589 patients with type 2 diabetes were enrolled, with a median follow-up of 11.0 years. After adjusting for age and sex, aDCSI (HR 1.21, 95% CI 1.20 to 1.21) and CCI (HR 1.18, 1.17 to 1.18) were associated with all-cause mortality. The HRs of aDCSI for cancer, cardiovascular disease (CVD) and diabetes mortality were 1.04 (1.04 to 1.05), 1.27 (1.27 to 1.28) and 1.28 (1.28 to 1.29), respectively, and the HRs of CCI were 1.10 (1.09 to 1.10), 1.16 (1.16 to 1.17) and 1.17 (1.16 to 1.17), respectively. The model with aDCSI had a better fit for all-cause, CVD and diabetes mortality with C-index of 0.760, 0.794 and 0.781, respectively. Models incorporating both scores had even better performance, but the HR of aDCSI for cancer (0.98, 0.97 to 0.98) and the HRs of CCI for CVD (1.03, 1.02 to 1.03) and diabetes mortality (1.02, 1.02 to 1.03) became neutral. When aDCSI and CCI were considered time-varying scores, the association with mortality was stronger. aDCSI had a strong correlation with mortality even after 8 years (HR 1.18, 1.17 to 1.18).
The aDCSI predicts all-cause, CVD and diabetes deaths but not cancer deaths better than the CCI. aDCSI is also a good predictor for long-term mortality.
适应性糖尿病并发症严重程度指数(aDCSI)是一种常用的严重程度衡量指标,基于使用诊断代码的糖尿病并发症的数量和严重程度。aDCSI 在预测特定原因死亡率方面的有效性尚未得到验证。此外,aDCSI 在预测患者预后方面的表现与 Charlson 合并症指数(CCI)相比仍然未知。
从台湾全民健康保险理赔数据中确定了 2008 年 1 月 1 日前患有 2 型糖尿病的 20 岁或以上的患者,并进行了随访,直到 2018 年 12 月 15 日。收集了 aDCSI 的并发症,包括心血管疾病、脑血管疾病和外周血管疾病、代谢疾病、肾病、视网膜病变和神经病变,以及 CCI 的合并症。使用 Cox 回归估计死亡的 HR。通过一致性指数和赤池信息量准则评估模型性能。
共纳入了 1002589 名 2 型糖尿病患者,中位随访时间为 11.0 年。调整年龄和性别后,aDCSI(HR 1.21,95%CI 1.20 至 1.21)和 CCI(HR 1.18,1.17 至 1.18)与全因死亡率相关。aDCSI 预测癌症、心血管疾病(CVD)和糖尿病死亡率的 HR 分别为 1.04(1.04 至 1.05)、1.27(1.27 至 1.28)和 1.28(1.28 至 1.29),CCI 的 HR 分别为 1.10(1.09 至 1.10)、1.16(1.16 至 1.17)和 1.17(1.16 至 1.17)。aDCSI 模型对全因、CVD 和糖尿病死亡率的拟合度更好,C 指数分别为 0.760、0.794 和 0.781。包含两个评分的模型表现更好,但 aDCSI 预测癌症的 HR(0.98,0.97 至 0.98)和 CCI 预测 CVD(1.03,1.02 至 1.03)和糖尿病死亡率(1.02,1.02 至 1.03)的 HR 变得中性。当 aDCSI 和 CCI 被视为时变评分时,与死亡率的关联更强。aDCSI 甚至在 8 年后仍与死亡率有很强的相关性(HR 1.18,1.17 至 1.18)。
aDCSI 预测全因、CVD 和糖尿病死亡的效果优于 CCI,但不能预测癌症死亡。aDCSI 也是长期死亡率的良好预测指标。